Iovance Biotherapeutics, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$11.4M
Doctors Paid
409
Transactions
1,464
2024 Total
$11.4M
Payment Breakdown by Category
Research$11.3M (99.0%)
Consulting$33,845 (0.3%)
Food & Beverage$26,679 (0.2%)
Travel$14,142 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $11.3M | 862 | 99.0% |
| Honoraria | $39,995 | 12 | 0.4% |
| Consulting Fee | $33,845 | 16 | 0.3% |
| Food and Beverage | $26,679 | 522 | 0.2% |
| Travel and Lodging | $14,142 | 52 | 0.1% |
Payments by Type
Research
$11.3M
862 transactions
General
$114,661
602 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| 101623 | $2.2M | 0 | 220 |
| TIL multiple tumor types | $1.2M | 0 | 9 |
| 81990 | $1.2M | 0 | 206 |
| 117145 | $827,238 | 0 | 132 |
| Phase II Pembro + HD IL-2 for MM and RCC | $799,177 | 0 | 2 |
| NCT03108495 | $786,417 | 0 | 90 |
| Phase II LD IL-2 CGVHD | $444,128 | 0 | 4 |
| NCT05361174 | $331,229 | 0 | 101 |
| IIT-2022-LDTIL | $324,622 | 0 | 3 |
| Phase II LD IL-2 + ECP for steroid refractory cGVHD | $321,985 | 0 | 2 |
| TIL in multiple tumor types | $277,574 | 0 | 1 |
| Phase II Daily LD IL-2 CGVHD | $222,059 | 0 | 2 |
| Phase I Reg.T cells+ LD IL-2 cGVHD | $222,059 | 0 | 2 |
| Phase II LD IL-2 CGVHD + ECP | $199,853 | 0 | 4 |
| Phase 1b pilot trial of IP IL-2 | $194,301 | 0 | 2 |
| NCT02360579 | $181,731 | 0 | 47 |
| Biomarker study A Biomarker Study of Low-Dose IL- 2 Plus Pembrolizumab in Patients with Stage IV Non- Small Cell Lung Cancer | $166,544 | 0 | 1 |
| Phase II Reg.Tcells IL-2 cGVHD | $166,544 | 0 | 2 |
| IOV-EAP-401 | $164,400 | 0 | 5 |
| 131462 | $141,705 | 0 | 3 |
| Phase Ib pilot trial of IP admin. IL-2 and systemic PD-1 inhibition in patients with gastric cancer and peritoneal metastasis | $113,235 | 0 | 1 |
| Phase I Randomized Open Label Trial Investigating Adoptive Transfer of CD39+CD103+CD8+ Tumor-isolated T Cells (AGX148) Alone or Combined With siRNA Modulation of PD-1 ( | $111,029 | 0 | 1 |
| Phase 1b/2a study Low Dose Sub cutaneous IL-2 in Crohns disease | $111,029 | 0 | 2 |
| CD40L-augmented (TIL) for Oncogene-Driven Advanced NSCLC | $99,926 | 0 | 1 |
| 123745 | $98,417 | 0 | 3 |
| 22-109 | $73,015 | 0 | 2 |
| Endometrial Preclinical Research: OU202308LH-IOVANCE | $56,170 | 0 | 1 |
| NK cell study | $44,412 | 0 | 2 |
| LD SC IL-2 in crohn's disease | $44,412 | 0 | 1 |
| Low dose Subc IL-2 for Crohn's Disease | $33,309 | 0 | 1 |
Payments by Medical Specialty
| Specialty | Total Paid | Doctors | Avg/Doctor |
|---|---|---|---|
| Hematology & Oncology | $39,734 | 92 | $431.89 |
| Internal Medicine | $22,459 | 60 | $374.32 |
| Surgery | $21,965 | 19 | $1,156 |
| Medical Oncology | $8,230 | 40 | $205.75 |
| Surgical Oncology | $7,528 | 12 | $627.34 |
| Specialist | $3,621 | 2 | $1,810 |
| Family | $1,812 | 56 | $32.35 |
| Student in an Organized Health Care Education/Training Program | $1,612 | 8 | $201.47 |
| Physician Assistant | $1,413 | 27 | $52.32 |
| Gynecologic Oncology | $1,400 | 1 | $1,400 |
| Family Medicine | $620.25 | 3 | $206.75 |
| Nurse Practitioner | $547.70 | 19 | $28.83 |
| Gastroenterology | $471.69 | 2 | $235.85 |
| Hematology | $463.82 | 8 | $57.98 |
| General Practice | $336.34 | 1 | $336.34 |
| Pediatrics | $323.92 | 2 | $161.96 |
| Acute Care | $302.32 | 8 | $37.79 |
| Registered Nurse | $253.09 | 6 | $42.18 |
| Radiation Oncology | $251.34 | 4 | $62.84 |
| Adult Health | $211.01 | 10 | $21.10 |
| Gerontology | $184.04 | 3 | $61.35 |
| Anatomic Pathology & Clinical Pathology | $149.72 | 1 | $149.72 |
| Military Health Care Provider | $122.64 | 1 | $122.64 |
| Surgical | $120.99 | 1 | $120.99 |
| Emergency Medicine | $90.15 | 2 | $45.07 |
| Hospitalist | $64.54 | 1 | $64.54 |
| Medical | $58.51 | 4 | $14.63 |
| Hospice and Palliative Medicine | $52.36 | 3 | $17.45 |
| Pediatric Hematology-Oncology | $47.54 | 1 | $47.54 |
| Primary Care | $33.59 | 2 | $16.80 |
| Home Health | $26.35 | 1 | $26.35 |
| Therapeutic Radiology | $23.10 | 1 | $23.10 |
| Psychiatric/Mental Health | $22.79 | 1 | $22.79 |
| Obstetrics & Gynecology | $22.44 | 1 | $22.44 |
| Critical Care Medicine | $19.15 | 1 | $19.15 |
| Oncology | $17.89 | 1 | $17.89 |
| Clinical Nurse Specialist | $17.76 | 1 | $17.76 |
| Pediatric Surgery | $16.81 | 1 | $16.81 |
| Cardiovascular Disease | $7.83 | 1 | $7.83 |
| Plastic Surgery | $7.83 | 1 | $7.83 |
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Joel Neal, M.d., Ph.d, M.D., PH.D | Hematology & Oncology | Stanford, CA | $13,875 | $0 |
| Amanda Kirane, Md, MD | Surgery | Palo Alto, CA | $10,812 | $0 |
| David Carbone, Md, Phd, MD, PHD | Hematology & Oncology | Columbus, OH | $7,767 | $0 |
| Dr. Benjamin Creelan, Md, Ms, MD, MS | Internal Medicine | Tampa, FL | $7,749 | $0 |
| Dr. Thach-Giao Truong, Md, MD | Medical Oncology | Cleveland, OH | $4,970 | $0 |
| Yazan Samhouri, Md, MD | Hematology & Oncology | Gilbert, AZ | $4,957 | $0 |
| James Millis | Surgical Oncology | Chicago, IL | $4,923 | $0 |
| Mr. Vijay Trisal, Md, MD | Surgery | Duarte, CA | $4,738 | $0 |
| Gary Doolittle, M.d, M.D | Hematology & Oncology | Westwood, KS | $4,727 | $0 |
| Michael Bishop | Hematology & Oncology | Chicago, IL | $4,373 | $0 |
| Dr. James Smithy, Md, MD | Internal Medicine | New York, NY | $4,254 | $0 |
| Dr. Charlotte Ariyan, Md, Phd, MD, PHD | Surgery | New York, NY | $4,236 | $0 |
| Dr. Janice Dutcher, M.d, M.D | Specialist | New York, NY | $3,500 | $0 |
| Jae Park, Md, MD | Internal Medicine | New York, NY | $3,196 | $0 |
| Frederick Locke, M.d, M.D | Internal Medicine | Tampa, FL | $2,848 | $0 |
| Genevieve Boland, Md, Phd, MD, PHD | Surgical Oncology | Boston, MA | $1,781 | $0 |
| Dr. Premal Thaker, Md, MD | Gynecologic Oncology | Saint Louis, MO | $1,400 | $0 |
| Adam Schoenfeld, Md, MD | Student in an Organized Health Care Education/Training Program | New York, NY | $1,047 | $0 |
| Adil Daud, Md, MD | Internal Medicine | Tampa, FL | $685.00 | $0 |
| Allison Betof Warner, Md, MD | Internal Medicine | Stanford, CA | $432.66 | $0 |
| Alexander Shoushtari, M.d, M.D | Medical Oncology | New York, NY | $418.27 | $0 |
| Dr. Adam Schoenfeld, M.d, M.D | Gastroenterology | New Britain, CT | $405.76 | $0 |
| Thach Truong, Md, MD | General Practice | San Bernardino, CA | $336.34 | $0 |
| Dr. Geoffrey Gibney, Md, MD | Internal Medicine | Washington, DC | $324.96 | $0 |
| Dr. Young Hong, M.d, M.D | Surgery | Camden, NJ | $320.26 | $0 |
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. has made $11.4M in payments to 409 healthcare providers, recorded across 1,464 transactions in the CMS Open Payments database. In 2024, the company paid $11.4M. The top product by payment volume is Amtagvi ($6.5M).
Payments were distributed across 40 medical specialties. The top specialty by payment amount is Hematology & Oncology ($39,734 to 92 doctors).
Payment categories include: Food & Beverage ($26,679), Consulting ($33,845), Research ($11.3M), Travel & Lodging ($14,142).
Iovance Biotherapeutics, Inc. is associated with 1 products in the CMS Open Payments database.